Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Royal Marsden Hospital, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:London
Treatments:Biologic therapyHospital:Royal Marsden Hospital
Drugs:Journal:Link
Date:Jul 2003

Description:

Patients: This Phase II study involved 76 patients with advanced breast cancer.

Treatment: The treatment consisted of oral administration of an inhibitor of farnesyl transferase (R115777 or Zarnestra). Patients were divided into two groups. One group of 41 women received the treatment in a continuous dosing regimen. The second group of 35 women received it in an intermittent dosing regimen.

Toxicity: For both groups of patients combined, toxicities included grade 4 hematologic toxicities, grade 3-4 fatigue, diarrhea, peripheral neuropathy, hypoaesthesia, muscle weakness, somnolence, and rash.

Results: The median overall survival for the patients who received the drug in continuous dosing was 15.1 months. (Median survival for the intermittent dosing group was 10.4 months.)

Support: The study was supported by Johnson & Johnson Pharmaceutical Research & Development which develops R115777.

Correspondence: Stephen R.D. Johnston, MD, PhD




Back